ILMN Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 39.06
- PEG ratio
- 3.58
- P/B
- 10.93
- P/S (TTM)
- 6.91
- EV/EBITDA
- 29.29
Profitability & growth
- ROE (TTM)
- 32.3%
- Operating margin
- 21.1%
- Revenue growth YoY
- 9.4%
- Dividend yield
- —
- Beta
- 1.47
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Illumina Inc
Company profileIllumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 5200 ILLUMINA WAY, SAN DIEGO, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
